Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07266441 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: TRIlogy-3
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Enrollment closed, study ongoing · Enrollment target: estimated 157 to confirmed 168 · Eligibility criteria expanded, about 12 words · 1 more Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Enrollment target: estimated 157 to confirmed 168
    • Eligibility criteria expanded, about 12 words
    • Site details revised at 71 of 71 sites
  2. Site details revised at 22 of 71 sitesv11
  3. Study sites: 69 to 71v10
  4. Trial sites expanded: 51 → 69 locationsv9
  5. Trial sites expanded: 37 → 51 locationsv8
  6. Trial sites expanded: 31 → 37 locationsv7
  7. Trial sites expanded: 23 → 31 locationsv6
  8. Study sites: 6 to 23v5
  9. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 6 · Start date changed from estimate of Feb 20, 2026 to Feb 8, 2026v4 Show 2 more changesShow less
    • Study sites: 0 to 6
    • Start date changed from estimate of Feb 20, 2026 to Feb 8, 2026
  10. Start date: Feb 24, 2026 to Feb 20, 2026v3
  11. Start date: Mar 17, 2026 to Feb 24, 2026 Eligibility criteria revisedv2 Show 1 more changeShow less
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  12. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Trial Details
NCT Number NCT07266441
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 168 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov